Outcomes and computed tomography radiomic features extraction in soft tissue sarcomas treated with neoadjuvant radiation therapy.
neoadjuvant radiotherapy
radiomic features
soft tissue sarcomas
Journal
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
ISSN: 1507-1367
Titre abrégé: Rep Pract Oncol Radiother
Pays: Poland
ID NLM: 100885761
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
03
2021
accepted:
21
05
2021
entrez:
11
11
2021
pubmed:
12
11
2021
medline:
12
11
2021
Statut:
epublish
Résumé
The aim of the study was to evaluate the management, toxicity and treatment responses of patients treated with neoadjuvant radiotherapy (NART) for soft tissue sarcomas (STS) and to analyse the potential of radiomic features extracted from computed tomography (CT) scans. This is a retrospective and exploratory study with patients treated between 2006 and 2019. Acute and chronic toxicities are evaluated. Local progression free survival (LPFS), distant progression free survival (DPFS) and overall survival (OS) are analysed. Radiomic features are obtained. A total of 25 patients were included. Median follow-up is 24 months. Complications in surgical wound healing were observed in 20% of patients, chronic fibrosis was documented as grade 1 (12%) and grade 2 (12%) without grade 3 events and chronic lymphedema as grade 1 (8%) and grade 2 (20%) without grade 3 events. Survival variables were LPFS 76%, DPFS 62% and OS 67.2% at 2-year follow-up. CT radiomics features were associated significantly with local control (GLCM-correlation), systemic control (HUmin, HUpeak, volume, GLCM-correlation and GLZLM-GLNU) and OS (GLZLM-SZE). STS treated with NART in our centre associate with an OS and toxicity comparable to other series. CT radiomic features have a prognosis potential in STS risk stratification. The results of our study may serve as a motivation for future prospective studies with a greater number of patients.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of the study was to evaluate the management, toxicity and treatment responses of patients treated with neoadjuvant radiotherapy (NART) for soft tissue sarcomas (STS) and to analyse the potential of radiomic features extracted from computed tomography (CT) scans.
MATERIALS AND METHODS
METHODS
This is a retrospective and exploratory study with patients treated between 2006 and 2019. Acute and chronic toxicities are evaluated. Local progression free survival (LPFS), distant progression free survival (DPFS) and overall survival (OS) are analysed. Radiomic features are obtained.
RESULTS
RESULTS
A total of 25 patients were included. Median follow-up is 24 months. Complications in surgical wound healing were observed in 20% of patients, chronic fibrosis was documented as grade 1 (12%) and grade 2 (12%) without grade 3 events and chronic lymphedema as grade 1 (8%) and grade 2 (20%) without grade 3 events. Survival variables were LPFS 76%, DPFS 62% and OS 67.2% at 2-year follow-up. CT radiomics features were associated significantly with local control (GLCM-correlation), systemic control (HUmin, HUpeak, volume, GLCM-correlation and GLZLM-GLNU) and OS (GLZLM-SZE).
CONCLUSIONS
CONCLUSIONS
STS treated with NART in our centre associate with an OS and toxicity comparable to other series. CT radiomic features have a prognosis potential in STS risk stratification. The results of our study may serve as a motivation for future prospective studies with a greater number of patients.
Identifiants
pubmed: 34760315
doi: 10.5603/RPOR.a2021.0092
pii: rpor-26-5-804
pmc: PMC8575355
doi:
Types de publication
Journal Article
Langues
eng
Pagination
804-813Informations de copyright
© 2021 Greater Poland Cancer Centre.
Déclaration de conflit d'intérêts
Conflict of interest The authors declare that there is no conflict of interest.
Références
Pathology. 2014 Feb;46(2):95-104
pubmed: 24378391
Cancer. 2013 May 15;119(10):1878-84
pubmed: 23423841
Radiother Oncol. 2019 Jun;135:187-196
pubmed: 30961895
Jpn J Clin Oncol. 2019 Feb 1;49(2):103-107
pubmed: 30423153
Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):498-505
pubmed: 20888702
Lancet. 2002 Jun 29;359(9325):2235-41
pubmed: 12103287
Clin Sarcoma Res. 2012 Oct 04;2(1):14
pubmed: 23036164
Cancer Chemother Pharmacol. 2016 Jan;77(1):133-46
pubmed: 26563256
J Clin Oncol. 2008 Jul 10;26(20):3440-4
pubmed: 18612160
Cancer Res. 2018 Aug 15;78(16):4786-4789
pubmed: 29959149
Ann Surg. 1982 Sep;196(3):305-15
pubmed: 7114936
Cancer. 2017 Aug 1;123(15):2802-2820
pubmed: 28493287
Ann Surg Oncol. 2010 May;17(5):1367-74
pubmed: 20217260